Table 3 Cancer-specific profile of survivors meeting neither, aerobic-only, strength-only, or combined exercise guidelines

Cancer type

.008

 Leukemia (n = 186)

96 (52%)

37 (20%)

17 (9%)

36 (19%)

 Hodgkin lymphoma (n = 187)

64 (34%)

47 (25%)

21 (11%)

55 (29%)

 non-Hodgkin lymphoma (n = 233)

121 (52%)

49 (21%)

20 (9%)

43 (19%)

Time since diagnosis

.11

  < 2 years (n = 116)

53 (46%)

19 (16%)

17 (15%)

27 (23%)

 2-5 years (n = 304)

137 (45%)

78 (26%)

21 (7%)

68 (22%)

  > 5 years (n = 186)

91 (49%)

36 (19%)

20 (11%)

39 (21%)

Radiation

.27

 No (n = 399)

196 (49%)

83 (21%)

38 (9%)

82 (21%)

 Yes (n = 207)

85 (41%)

50 (24%)

20 (10%)

52 (25%)

Chemotherapy

.64

 No (n = 173)

81 (47%)

38 (22%)

20 (12%)

34 (20%)

 Yes (n = 433)

200 (46%)

95 (22%)

38 (9%)

100 (23%)

Stem cell/marrow transplant

.35

 No (n = 541)

255 (47%)

121 (22%)

50 (9%)

115 (21%)

 Yes (n = 65)

26 (40%)

12 (19%)

8 (12%)

19 (29%)

Treatment status

.13

 Receiving treatments (n = 193)

99 (51%)

38 (20%)

22 (11%)

34 (18%)

 Completed treatments (n = 413)

182 (44%)

95 (23%)

36 (9%)

100 (24%)

Recurrence

.88

 No (n = 524)

242 (46%)

113 (22%)

54 (10%)

118 (23%)

 Yes (n = 82)

39 (48%)

20 (24%)

7 (9%)

16 (20%)

Current cancer status

.007

 Disease free (n = 372)

156 (42%)

88 (24%)

32 (9%)

96 (26%)

 Existing disease (n = 234)

125 (53%)

45 (19%)

26 (11%)

38 (16%)

Comorbidities

<.001

 None (n = 221)

72 (33%)

56 (25%)

25 (11%)

68 (31%)

 One (n = 151)

61 (40%)

42 (28%)

12 (8%)

36 (24%)

 Two or more (n = 234)

148 (63%)

35 (15%)

21 (9%)

30 (13%)

Exercise recommendation

.07

 No (n = 376)

185 (49%)

86 (23%)

36 (10%)

69 (18%)

 Yes (n = 230)

96 (42%)

47 (20%)

22 (10%)

65 (28%)